Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

The Evolving Role of TKIs in First-line Treatment of Advanced HCC

In this podcast episode, experts Josep M. Llovet, MD, PhD, and Univ. Prof. Markus Peck-Radosavljevic, MD, MBA, discuss the evolving role of tyrosine kinase inhibitors in the first-line treatment of patients with advanced hepatocellular carcinoma.
Josep M. Llovet, MD
Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA
Released: December 14, 2021

Information on this Educational Activity

Faculty

Josep M. Llovet, MD

Professor of Medicine
Director,
Mount Sinai Liver Cancer Program
Division of Liver Diseases
Mount Sinai School of Medicine
Professor of Research
Liver Unit, IDIBAPS
Hospital Clínic Barcelona
Barcelona, Spain

Josep M. Llovet, MD, PhD, FAASLD, has disclosed that he receives funds for contracted research from Bayer HealthCare Pharmaceuticals, Boehringer-Ingelheim, Bristol Myers Squibb, Eisai, and Ipsen Pharma and consulting fees from Bayer Healthcare Pharmaceuticals, Boehringer-Ingelheim, Bristol Myers Squibb, Celson Corporation, Eisai, Eli Lilly, Exelixis, Ipsen Pharma, and Merck.
Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA

Professor of Medicine
Medical University of Vienna
Vienna, Austria
Department Chair
Innere Medizin und Gastroenterologie
Klinikum Klagenfurt am Wörthersee
Klagenfurt am Wörthersee, Austria

Markus Peck-Radosavljevic, MD, MBA, has disclosed that he receives consulting fees from Bayer HealthCare Pharmaceuticals, Eisai, Gilead Sciences, Ipsen, Lily, and Roche and fees for non-CME/CE services from Bayer Healthcare, Bristol Myers Squibb, Eisai, Gilead Sciences, Ipsen, Lilly, MSD, and Roche.

Program Medium

This program has been made available online.

Acknowledgements

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Downloadable slideset with highlights from key gastrointestinal cancers as presented at 2022 ESMO World Congress on Gastrointestinal Cancer, from Clinical Care Options (CCO)

Released: August 16, 2022

Patient-reported outcomes from the HIMALAYA study of durvalumab with or without tremelimumab vs sorafenib in unresectable hepatocellular carcinoma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 6, 2022

Experts highlight key studies being presented at the 2022 ASCO Annual Meeting in this commentary from Clinical Care Options (CCO)

Allison Betof Warner, MD, PhD John M. Burke, MD Shaji K. Kumar, MD Christopher H. Lieu, MD Stephen V. Liu, MD Joyce O'Shaughnessy, MD Zofia Piotrowska, MD, MHS Angeles Alvarez Secord, MD, MHSc Rachna Shroff, MD Hussein Tawbi, MD, PhD Eunice S. Wang, MD Released: June 1, 2022

Clinical Care Options (CCO): Experts review key data for gastric, rectal, liver, hepatobiliary tract, and pancreas cancers from the 2022 ASCO Gastrointestinal Cancers Symposium and the ASCO Plenary Series

Manish A. Shah, MD Rachna Shroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 20, 2022 Expired: April 19, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings